Paul Khavari

DermTech Presents Research Abstracts at the 2024 American Academy of Dermatology (AAD) Annual Meeting and New Research Published in the Journal of Investigative Dermatology

Retrieved on: 
Friday, March 8, 2024
Oncology, Health, Stem Cells, Genetics, General Health, Research, Science, Skin cancer, DMT, NPV, MD, Melanoma, Skin, TP53, Paul Khavari, AAD, NOTCH1, Abstract, Patient, Journal, Trial of the century, DNA, American Academy

DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced the presentation of two research abstracts at the 2024 American Academy of Dermatology (AAD) Annual Meeting, taking place March 8th-12th in San Diego, California.

Key Points: 
  • DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today announced the presentation of two research abstracts at the 2024 American Academy of Dermatology (AAD) Annual Meeting, taking place March 8th-12th in San Diego, California.
  • “This real-world clinical study demonstrates that the DMT can help clinicians improve outcomes for cutaneous melanomas in patients of all skin types,” commented Dr. Skelsey.
  • The research found that somatic mutations in healthy-appearing sun-exposed skin indicate an increased risk for skin cancer.
  • Furthermore, these mutations capture skin cancer risk information that is not accounted for by other risk factors.

INTERNATIONALLY RENOWNED DERMATOLOGIST AND PHYSICIAN SCIENTIST SHAWN KWATRA, MD, NAMED NEW CHAIR OF DERMATOLOGY AT THE UM SCHOOL OF MEDICINE AND CHIEF OF SERVICE OF DERMATOLOGY AT UM MEDICAL CENTER

Retrieved on: 
Monday, September 18, 2023
The New England Journal of Medicine, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Medical Affairs Bureau, Society, University of Maryland, College Park, Atopic dermatitis, Skin condition, Science, Maryland School, JAMA Dermatology, Hospital, Journal, Faculty, Prurigo nodularis, University, Physician, Service, Research, Paul Khavari, Johns Hopkins School of Medicine, Human musculoskeletal system, Knowledge, NIH, Skin, Duke University, Arthritis, Immunotherapy, FPI, University of Maryland School of Medicine, Diving Medical Advisory Council, MPH, University of Maryland Medical Center, Vinay Mohan Kwatra, UMMC, Wake Forest School of Medicine, Nature Medicine, UMMS, Joseph, Assistant professor, Pharmaceutical industry, Management, Medical device, Nursing, MD, Dermatology

Dr. Kwatra, who will begin the new role in early 2024, will hold the Joseph W. Burnett Endowed Professor and Chair in Dermatology.

Key Points: 
  • Dr. Kwatra, who will begin the new role in early 2024, will hold the Joseph W. Burnett Endowed Professor and Chair in Dermatology.
  • Dr. Kwatra joins UMSOM from Johns Hopkins University School of Medicine, where he served as the Founding Director of the Johns Hopkins Itch Center.
  • "It is an honor to be the next Chair of Dermatology at such a prestigious medical school," said Kwatra.
  • He earned his undergraduate degree from Duke University and his medical degree from Wake Forest University School of Medicine.

Late-Breaking Turn Biotechnologies Presentation at ISID to Show Cell Reprogramming with ERA™ Technology Renews Skin

Retrieved on: 
Wednesday, May 10, 2023
Matrix metalloproteinase, Paul Khavari, ISID, Matrix metalloproteinase inhibitor, Regeneration, Research, Cell, Messenger, ERA, Cellular senescence, Oxidative stress, International Society for Infectious Diseases, Extracellular matrix, ECM, Wound healing, Shinjuku, Epigenetics, Shinjuku NS Building, Skin, JST, Medical device, Dermatology, Ageing

MOUNTAIN VIEW, Calif., May 10, 2023 /PRNewswire/ -- Turn Biotechnologies, a cell reprogramming company developing novel mRNA medicines for untreatable, age-related conditions, has been invited to present data showing that its epigenetic reprogramming technology rejuvenates human skin.

Key Points: 
  • MOUNTAIN VIEW, Calif., May 10, 2023 /PRNewswire/ -- Turn Biotechnologies, a cell reprogramming company developing novel mRNA medicines for untreatable, age-related conditions, has been invited to present data showing that its epigenetic reprogramming technology rejuvenates human skin.
  • Turn Bio's late-breaking abstract was accepted for presentation during the prestigious International Societies for Investigative Dermatology (ISID) Meeting, in Tokyo, Japan.
  • Data will show that transient reprogramming with Turn Bio's Epigenetic Reprogramming of Aging (ERA™) technology rejuvenates cells within the extracellular matrix (ECM), resulting in comprehensive changes related to improved skin quality and structure.
  • Turn Bio data will be presented by Dr. Edward Hsia, vice president of Dermatology at Turn Bio.

ASLAN Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Friday, April 28, 2023
Abstract, Purchasing, Partnership, Executive director, Leo Pharma, Marketing, ISID, ASLN, ADS, TMO, Atopic dermatitis, Thermo Fisher Scientific, Neck, Associate, HCP, Sale, Yale School of Medicine, Alopecia areata, Development, Paul Khavari, Type 2, Journal, MD, Patient, Investment, International Society for Infectious Diseases, SAN, Autoimmune disease, Sanofi, Power purchase agreement, IL4R, Tralokinumab, Research, AD, NYSE, Safety, Pharmaceutical industry, Cryptocurrency, Video game, Head, Dermatology, AA

“We have also advanced farudodstat into a Phase 2a, proof-of-concept study in alopecia areata (AA) expected to commence enrollment in the second quarter of 2023.

Key Points: 
  • “We have also advanced farudodstat into a Phase 2a, proof-of-concept study in alopecia areata (AA) expected to commence enrollment in the second quarter of 2023.
  • The trial will recruit around 60 AA patients in the US and enrollment is expected to begin in the second quarter of 2023.
  • Research and development expenses were $14.1 million in the first quarter of 2023 compared to $9.4 million in the first quarter of 2022.
  • General and administrative expenses were $4.0 million in the first quarter of 2023 compared to $2.5 million in the first quarter of 2022.

ASLAN Pharmaceuticals Announces Four Abstracts on Eblasakimab and Farudodstat, Including Two Late-Breakers, to be Presented at the 1st International Societies for Investigative Dermatology Meeting

Retrieved on: 
Monday, April 24, 2023
Learning, Abstract, Neuron, Psoriasis Area and Severity Index, ASLN, Hair, DHODH, Head, Research, Neck, Immune privilege, MRGPRX2, Paul Khavari, Journal, Patient, International Society for Infectious Diseases, SAN, Interleukin, Drug development, Itch, Cytokine, AD, Pharmacology, Skin, JST, Medical imaging, Copper, Pharmaceutical industry, EASI, ISID

Two further abstracts on eblasakimab, which were earlier accepted for presentation at the ISID meeting, have been published online in the Journal of Investigative Dermatology.

Key Points: 
  • Two further abstracts on eblasakimab, which were earlier accepted for presentation at the ISID meeting, have been published online in the Journal of Investigative Dermatology.
  • “The abstracts published today highlight the potential of eblasakimab to offer important differentiated benefits for AD patients.
  • Spontaneous neuronal activity was not impacted by IL-13 treatment but was increased with IL-4 treatment, which was also effectively reduced by eblasakimab.
  • This indicates that direct impact on neuronal responses may contribute to reduction of chronic itch demonstrated in AD patients treated with eblasakimab.